[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognition-disorders-in-old-age\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognition-disorders-in-old-age":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,76,107,137,163,193,221,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637439","study-on-the-effectiveness-and-safety-of-two-olive-extract--based-olea-europea-l-folium-supplements-alone-or-combined-with-a-mullein-extract-verbascum-thapsus-l-herba-cum-floribus-for-the-maintenance-of-cognitive-function-100637439",false,"NCT07586410","Study on the Effectiveness and Safety of Two Olive Extract- Based (Olea Europea L. Folium) Supplements, Alone or Combined With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function.","Efficacy and Tolerability Study of Two Food Supplements, the First Based on an Olive Extract (Olea Europea L. Folium) and the Second on the Combination of the Latter With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function: a Single-center, Randomized, Placebo-controlled, Parallel-arm, Double-blind Clinical Study.","Participants of both sexes who meet the following characteristics will be included in the study:\n\n* aged between 60 and 85 years;\n* able to understand and sign the informed consent form;\n* able to understand and comply with the protocol requirements;\n* negative HIV test;\n* score between 20 and 25 on the Montreal Cognitive Assessment (MoCA) questionnaire (Nasreddine et al., 2005).\n* total Instrumental Activities of Daily Living (IADL) + Activities of Daily Living (ADL) score of 14;\n* Geriatric Depression Scale (GDS) score between 0 and 5;\n* Generalized Anxiety Disorder (GAD-7) score between 0 and 4;\n* not currently taking or taking any medications, including antidiabetics, drugs that affect the nervous system such as antidepressants, anxiolytics, or opioids;\n* who are not taking antibiotics or have not taken antibiotics in the last four weeks, or in the last 6 months, based on the intensity and duration of antibiotic treatment.\n\nSubjects with the following characteristics will be excluded from the study:\n\n* aged \\\u003C 60 and \\> 85 years;\n* individuals with a MoCA questionnaire score \\\u003C 20 and \\> 26;\n* Geriatric Depression Scale (GDS) score \\> 5;\n* Generalized Anxiety Disorder (GAD-7) score \\> 4;\n* who show no willingness to cooperate;\n* who have difficulty traveling to the referral facility on time;\n* who are deemed unsuitable by the investigator due to the presence of other conditions deemed incompatible with enrollment and which require pharmacological treatments (e.g., active systemic diseases, diabetes, neurological and psychiatric conditions, including cognitive disorders that prevent completion of the questionnaires);\n* affected by HIV-acquired immunodeficiency;\n* individuals with severe visual and hearing impairments;\n* with known allergies to ingredients of the investigational products (active or placebo);\n* who abuse alcohol, drugs, nicotine, caffeine, or theine;\n* who take medications.",true,"ALL","60 Years","85 Years",{"count":21,"type":22},99,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if two food supplements based on olive leaf extract, alone or combined with mullein extract, help maintain cognitive function in older adults with mild cognitive impairment (MCI). It will also evaluate their safety. The main questions it aims to answer are:\n\nDo the supplements improve or help maintain cognitive function (such as memory and attention)? Do participants experience any side effects when taking the supplements?\n\nResearchers will compare two active supplements to a placebo (a look-alike substance with no active ingredients) to see if the supplements are effective.\n\nParticipants will:\n\nTake either one of the two supplements or a placebo every day for 6 months Take 2 capsules per day, preferably between meals, with a small amount of water Visit the clinic at the start of the study, after 3 months, and after 6 months for cognitive assessments Complete questionnaires to evaluate cognitive function and quality of life Be monitored throughout the study for any side effects",[28],"Cognition Disorders in Old Age",[30,31,32,33,34],"cognitive decline","elderly people","food supplement","congitive function","preventivon","NOT_YET_RECRUITING","2026-05-08",{"date":38,"type":39},"2026-05-14","ACTUAL",{"date":41,"type":22},"2026-05-05",{"date":43,"type":22},"2026-11",{"name":45,"class":46},"ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100621981","real-world-clinical-response-to-trazodone-in-italy-poland-and-romania-100621981","NCT07377682","Real-world Clinical Response to Trazodone in Italy, Poland, and Romania","Observational Prospective Study in Patients With Major Depressive Disorder and Mild Cognition Impairment Treated With Trazodone in a Real-world Setting (TRACOMDD)","Inclusion Criteria:\n\n* Patients aged 55 or older.\n* Patients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for MDD diagnosis.\n* Patients experiencing a current major depressive episode of at least moderate severity, defined by a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20 at enrolment.\n* Patients with a diagnosis of MCI (also referred to as \"mild neurocognitive disorder\") according to the DSM-5 criteria.\n* Patients who start treatment with trazodone hydrochloride (prolonged release) with starting dosage according to SmPC at enrolment visit (or at latest within one week).\n* Patients legally capable of giving their written consent to participate in the study (including personal data processing) and willing to comply with all study procedures as per clinical judgement.\n\nExclusion Criteria:\n\n* Patients who meet any of the contraindications to the administration of trazodone according to the approved local SmPC.\n* Known hypersensitivity or allergy to the active ingredient and\u002For to any component of the study medication.\n* Concomitant treatment with other antidepressant drugs, mood stabilizers, antipsychotics, and\u002For proved resistance to trazodone monotherapy.\n* Patients with current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition.\n* Patients with previous or current history of any neurological condition that, in the opinion of the Investigator, might compromise participation in the study.\n* Patients participating in any interventional study in the 30 days prior to the enrolment visit.\n* Patients with ongoing pregnancy or breast-feeding at enrolment visit.","55 Years",{"count":57,"type":22},120,"OBSERVATIONAL","TRACOMDD study is a study with the intention to describe the real-world use of trazodone and the clinical response in a sub-group of patients affected by Major Depressive Disorder and Mild Cognitive impairment, by collecting data from standard clinical practice in Italy, Poland, and Romania",[61,28],"Depression - Major Depressive Disorder",[63,64,65],"Depression","Major Depressive Disorder","Cognition","RECRUITING","2026-01-22",{"date":69,"type":39},"2026-01-30",{"date":71,"type":39},"2025-12-15",{"date":73,"type":22},"2026-07",{"name":75,"class":46},"Aziende Chimiche Riunite Angelini Francesco S.p.A",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100618981","phase-2-evaluation-of-the-effect-of-l-arginine-on-the-cognitive-function-in-geriatric-patients-100618981","NCT07338682","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients","Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients, A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age \\>60 years\n* Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment)\n\nExclusion Criteria:\n\n* Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis)\n* Patients with history of L-arginine intolerance or allergy\n* Patients with asthma\n* Patients who recently had an acute myocardial infarction\n* Patients with history of stroke within 1 yaear\n* Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period.\n* Patients who initiated or stopped antihypertensive medications during the study period.\n* Patients who initiated or stopped antidiabetic medications during the study period.\n* Patients who initiated or stopped antihyperlipidemic medications during the study period.\n* Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function\n* Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics\n* Refusal to provide written informed consent",{"count":84,"type":22},60,[86],"PHASE2","This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.",[28,89],"Cognitive and Behavioral Impairment",[91,92,93,94,95,96],"L-arginine","Cognitive impairment","Geriatrics","Elderly","Cognitive Function","Nitric Oxide","2026-01-18",{"date":99,"type":39},"2026-01-21",{"date":101,"type":39},"2025-08-27",{"date":103,"type":22},"2026-06-30",{"name":105,"class":106},"German University in Cairo","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":47},"100587359","lsvt-big-and-dual-task-training-in-cognitive-impaired-patients-100587359","NCT06927362","LSVT Big and Dual Task Training in Cognitive Impaired Patients","Effects of Lee Silverman Voice Treatment Big and Dual Task Training on Balance, Cognition and Functional Mobility in Older Adults With Cognitive Impairment.","Inclusion Criteria:\n\n* Both male and female patients.\n* Age limit for patients will be above 65.\n* Patients with Mild and moderate cognitive impairment patients MoCA 13-25.\n* Patients with Berge balance scale value 41-50.\n* Patients who give consent to participate in study and undergo relevant test.\n\nExclusion Criteria:\n\n* Patients with any musculoskeletal disorder in which these exercises are contraindicated.\n* Patients using any walking aids.\n* Patients with hearing impairment.\n* Patients with other neurological conditions with limit the patient participation in planned exercise like stroke, Parkinson's.\n* Patients with diagnosed psychiatric disorder or taking medication that affect cognitive function within 24 hours.","65 Years",{"count":116,"type":22},50,[25],"The goal of this study ifs to determine the comparative effects of Lee Silverman voice treatment Big and dual task training on balance, cognition and functional mobility in older adults with cognitive impairment.\n\nPerform LSVT big four times in a week for about 4 months. Perform dual task training four times in a week for about 4 months. Complete assessments at baseline, the 4th, 8th, 12th weeks, and a follow-up at the 16th week.\n\nOutcome measures include Mini BESTest, MoCA, stroop test and time up and go test. Statistical analyses will assess within-group and between-group effects based on data distribution.",[120,121,28,122],"Cognitive Impairment","Balance Changes","Functional Mobility",[124,125,126,127],"LSVT big","dual task training","cognitive impaired patients","cognition","2025-08-18",{"date":130,"type":39},"2025-08-22",{"date":132,"type":39},"2025-04-10",{"date":134,"type":22},"2025-10-30",{"name":136,"class":106},"Riphah International University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100476270","neuropsychological-assessment-of-the-oldest-old-populationneuropsic-gr-100476270","NCT05481749","Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR)","Neuropsychological Assessment Of The Non-institutionalized Oldest-Old Population. Multicenter Normative Study.","NEUROPSIC-GR","Inclusion Criteria:\n\n* 80 or more years old\n* Residence at Comarca del Garraf\n* Able to be transfered to study center\n* Sufficient reading and writing capacity to carry out the neuropsychological tests, at the evaluator's discretion.\n\nExclusion Criteria:\n\n* Patient at end-of-life situation or with a very short life expectancy (days-weeks).\n* Hospital admission in the previous 3 months.\n* History of relevant mental illness: major depression, psychosis, bipolar disorder, obsessive-compulsive disorder.\n* Disease of the central nervous system with possible cognitive impairment: Parkinson's disease, multiple sclerosis, brain tumor, stroke with cognitive impairment, epilepsy, severe traumatic brain injury.\n* History of alcoholism or substance abuse.\n* Severe sensory deficit that prevents performing neuropsychological tests, at the discretion of the evaluator.\n* Positive Shortened Spanish Informant Questionnaire for Cognitive Decline in the Elderly questionnaire (SS-IQCODE) or Lobo's Cognitive Mini-examination Test (spanish adaptation of Minimental of Folstein test) with a score \\\u003C 23 (20 in people with low schooling or illiteracy).\n* Dementia criteria according to the Diagnostic and Statistical Manual of Mental Disorders IV.","80 Years",{"count":57,"type":22},"Neuropsychological tests currently considered to evaluate the cognitive performance of the oldest-old population (more than 80 years) are not adapted to this group population. This trial aims to determine the normal limits for this group population of a set of 18 neuropsychological test. Results may improve the diagnostic cognitive evaluation of this population.",[149,28],"Dementia",[151,152,149,28],"Geriatric Assessment","Aged, 80 and over","2025-06-23",{"date":155,"type":39},"2025-06-26",{"date":157,"type":39},"2023-02-14",{"date":159,"type":22},"2026-03",{"name":161,"class":106},"Consorci Sanitari de l'Alt Penedès i Garraf",6,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":19,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100530033","early-phase-1-probiotics-in-mild-alzheimers-disease-100530033","NCT06181513","Probiotics in Mild Alzheimer's Disease","Effect of Probiotics on Cognitive Functioning of Patients With Mild Alzheimer's Disease","Inclusion Criteria:\n\n* Adults ≥65 years, able to give consent\n* Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)\n* approximately equal male:female ratio\n\nExclusion Criteria:\n\n* Inability to give consent\n* other neurological disease\n* relevant psychiatric disorders (e.g. major depression)\n* gastrointestinal\u002Fmetabolic conditions\n* history of alcohol\u002Fsubstance dependence\n* use of systemic antibiotics in the previous 6 months\n* corticosteroid use\n* immune stimulating medications\n* immunosuppressive agents\n* probiotics consumption in the previous 6 months.\n* immunosuppression\n* structural heart disease\n* neutropenia\n* radiation\n* active intestinal disease",{"count":171,"type":22},40,[173],"EARLY_PHASE1","The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).",[176,28],"Neurodegenerative Diseases",[178,179,180,181,182,183],"probiotics","Electroencephalogram (EEG)","cognitive function","Alzheimer's Disease","neuropsychological testing","Electrocardiogram (EKG)","2024-12-03",{"date":186,"type":39},"2024-12-05",{"date":188,"type":39},"2022-12-19",{"date":190,"type":22},"2025-12-01",{"name":192,"class":106},"University of Nicosia",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":16,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":204,"conditions":205,"keywords":210,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100336232","alzheimers-disease-treatment-with-combination-of-40hz-light-and-cognitive-therapy-100336232","NCT03657745","Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy","An Observational Trial of Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy","AlzLife","Inclusion Criteria:\n\n* Alzheimer's disease\n* Cognitive Impairment\n\nExclusion Criteria:\n\n* any previously noted epileptic seizures, including febrile seizures.\n* any significant disease of the eye, such as macular degeneration. Since the 40Hz light therapy is delivered via eye stimulation, healthy eyes are required.","50 Years",{"count":203,"type":22},2000,"Electrical activity in the brain known as \"gamma\" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https:\u002F\u002Fwww.alz.life\u002F) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.",[206,207,149,28,208,209],"Alzheimer Disease","Mild Cognitive Impairment","Cognitive Decline","Cognitive Deterioration",[206,211,149],"Alzheimer's","2024-07-31",{"date":214,"type":39},"2024-08-01",{"date":216,"type":39},"2018-01-01",{"date":218,"type":22},"2029-12-31",{"name":220,"class":46},"Alzheimer's Light LLC",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":16,"sex":17,"minAge":201,"maxAge":19,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":241,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":47},"100525638","brain-health-virtual-reality-study-100525638","NCT06124339","Brain Health Virtual Reality Study","Interventions to Promote Brain Health Virtual Reality Study","Inclusion Criteria:\n\n1. 50-85 years of age\n2. Fluent in English\n3. Can safely ride a stationary bike\n\nExclusion Criteria:\n\n1. Dementia\n2. History of a neurological disorder\n3. Severe sensory deficits\n4. Inability to perform intervention (e.g., inability to cycle safely)\n5. Contraindications to MRI scan (e.g., pacemaker)\n6. Fear of needles\u002F blood\n7. Prior history of fainting due to sight of needles of blood",{"count":229,"type":22},150,[25],"The Interventions for Brain Health Virtual Reality Study is a NIH-funded clinical research trial at the University of California San Diego (UCSD) Health under the supervision of the study principal investigator Dr. Judy Pa. The overarching goal of this trial is to use a novel virtual reality (VR) based intervention that simultaneously engages physical and cognitive activity aimed at improving brain health and cognition in older adults. The investigators will compare 3 types of interventions: physical activity, VR cognitive activity, and combined VR physical and cognitive activity over 16 weeks to evaluate physical and brain health changes.",[233,234,235,236,237,238,239,207,208,240,28],"Aging","Aging Problems","Memory Loss","Memory Impairment","Memory Disorders in Old Age","Memory Disorder, Spatial","Memory Disorders","Cognitive Change",[242,243,244,245,246,247,248,249],"Virtual Reality","technology","intervention","exercise","cycling","memory","brain health","aging","2024-07-08",{"date":252,"type":39},"2024-07-10",{"date":254,"type":39},"2023-08-08",{"date":256,"type":22},"2029-02-01",{"name":258,"class":106},"University of California, San Diego",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":16,"sex":17,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":47},"100534522","cognitive-and-neural-assessment-platform-and-localized-norm-for-macau-older-adults-100534522","NCT06239922","Cognitive and Neural Assessment Platform and Localized Norm for Macau Older Adults.","Establishing Cognitive and Neural Assessment Platform and Localized Norm for Macau Older Adults","Inclusion Criteria:\n\n* Must be a local adult resident of Macau\n* Age above 50 years for older adult cohort\n* Younger adults individuals above 18 will be included as control comparators\n\nExclusion Criteria:\n\n* History of neurological injury or disease\n* Current use of medications that affect brain function or blood flow\n* Contraindications to MRI scanning, such as the presence of an electric\u002Fmechanical implant or device (e.g., pacemaker)\n* Claustrophobia\n* Body weight over 300 lbs due to weight and physical constraints of the scanner (i.e., bore size limited to 55 cm)\n* Inability to provide informed consent\n* Pregnancy\n* Being under the legal age of adulthood (children)\n* Incarcerated individuals (prisoners)","18 Years",{"count":268,"type":22},300,"The current project is dedicated to creating a comprehensive cognitive and neural assessment platform and corresponding norms tailored specifically to the older adults in Macau.",[28,208,120,271,240,233],"Cognitive Dysfunction",[273,274],"Macau","cognitive aging","2024-01-25",{"date":277,"type":39},"2024-02-02",{"date":279,"type":22},"2024-02",{"date":281,"type":22},"2026-12-30",{"name":283,"class":106},"University of Macau"]